Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial

Ubrogepant is a novel, oral calcitonin gene–related peptide receptor antagonist currently under US Food and Drug Administration (FDA) review for the acute treatment of migraine attacks. This double‐blind, four‐period crossover study compared the cardiac repolarization effect of therapeutic (100 mg)...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Pharmacol Ther
Hlavní autoři: Jakate, Abhijeet, Boinpally, Ramesh, Butler, Matthew, Lu, Kaifeng, McGeeney, Danielle, Periclou, Antonia
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7158215/
https://ncbi.nlm.nih.gov/pubmed/31628854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1696
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky